Status:
UNKNOWN
Evaluate the Therapeutic Effect of Inhaled Corticosteroid in Asthmatic Children
Lead Sponsor:
National Taiwan University Hospital
Collaborating Sponsors:
Academia Sinica, Taiwan
Conditions:
Asthma
Eligibility:
All Genders
5-18 years
Brief Summary
Inhaled corticosteroid (ICS) is considered the first line medication for asthma, however, the therapeutic effect is markedly different even in patients with almost similar clinical manifestations. Our...
Detailed Description
The three major common classes of asthma controller medications include inhaled corticosteroids (ICS), beta-2-agonists and leukotriene antagonists. Among them, ICS was now suggested as the first-line ...
Eligibility Criteria
Inclusion
- Diagnosed by asthma specialists, the age of onset was under 10 years old
Exclusion
- Children with cancer, major immunological diseases, such as systemic lupus erythematosus (SLE) or Henoch-Schonlein purpura (HSP), rare hereditary diseases, or under severe infection.
- Children who received ICS or oral steroid in recent 4 weeks
Key Trial Info
Start Date :
October 22 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03487809
Start Date
October 22 2016
End Date
December 31 2025
Last Update
September 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NTUH
Taipei, Taiwan